Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | PPARA | Q07869 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 5/20 | 0.52 |
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | FABP2 | P12104 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5321440 | 0.85 | POLB (0.54) | ACACBPPARGPPARACNR1CNR2 | |
| SCHEMBL25890576 | 0.83 | ACACB (0.67) | ACACBNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL14399160 | 0.81 | PPARG (0.43) | ACACBPPARGPPARACNR1CNR2 | |
| SCHEMBL14398214 | 0.81 | MEN1 (0.49) | NPC1RAB9APPARGPPARACNR1 | |
| SCHEMBL880676 | 0.81 | RAB9A (0.79) | ACACBNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL11949543 | 0.81 | RAB9A (0.79) | ACACBNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL5322668 | 0.81 | CNR1 (0.46) | ACACBPPARGPPARACNR1CNR2 | |
| SCHEMBL5321265 | 0.81 | PPARA (0.44) | ACACBPPARGPPARACNR1CNR2 | |
| SCHEMBL14397275 | 0.79 | NR1H4 (0.49) | ACACBPPARGPPARACNR1CNR2 | |
| SCHEMBL5326505 | 0.79 | NR1H4 (0.49) | ACACBPPARGPPARACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | claimed |
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1781303-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | CombinatoRx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | ACACB 36/4885NPC1 369/4885RAB9A 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.